Article
Oncology
Ella A. Eklund, Clotilde Wiel, Henrik Fagman, Levent M. Akyurek, Sukanya Raghavan, Jan Nyman, Andreas Hallqvist, Volkan Sayin
Summary: This retrospective study investigated the impact of KRAS mutational status on clinical outcome in patients with metastatic non-small cell lung cancer (NSCLC). The results showed that KRAS(MUT) patients had better response to immune checkpoint blockade (ICB) but worse response to platinum doublet chemotherapy (PT). Additionally, KRAS(WT) patients with high PD-L1 expressing tumors responded better to PT than ICB.
Article
Oncology
Jane Yanagawa, Gregory J. Riely
Summary: Significant advances have been made in the treatment of resectable non-small cell lung cancer (NSCLC) and metastatic NSCLC, including the use of neoadjuvant nivolumab + chemotherapy and adjuvant atezolizumab, as well as molecular testing for various gene mutations and targeted therapies.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2022)
Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, Stefan Michiels, Judith Raimbourg, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Elisabeth Quoix, Julien Mazieres, Denis Moro-Sibilot, Eric Dansin, Olivier Molinier, Hugues Morel, Eric Pichon, Alexis Cortot, Josiane Otto, Francois Chomy, Pierre-Jean Souquet, Nicolas Cloarec, Etienne Giroux-Leprieur, Ivan Bieche, Ludovic Lacroix, Sandrine Boyault, Valery Attignon, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Filippo Gustavo Dall'Olio, Marta Jimenez, Jean-Charles Soria, Benjamin Besse
Summary: Targeted therapies and immune checkpoint blockers have revolutionized the treatment of non-small cell lung cancer. This study investigated the use of targeted therapies and immune checkpoint blockers as maintenance therapy based on molecular characterization. The results showed no significant differences in progression-free survival between targeted therapies and standard-of-care, and immune checkpoint blockers showed enhanced benefits in patients with PD-L1 >= 1%.
CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Sun Min Lim, Solange Peters, Ana Laura Ortega Granados, Gustavo dix Junqueira Pinto, Christian Sebastian Fuentes, Giuseppe Lo Russo, Michael Schenker, Jin Seok Ahn, Martin Reck, Zsolt Szijgyarto, Neda Huseinovic, Eleftherios Zografos, Elena Buss, Neda Stjepanovic, Sean ODonnell, Filippo de Marinis
Summary: This study compared the efficacy and safety of two different anti-PD-1 antibodies, dostarlimab and pembrolizumab, combined with chemotherapy as first-line treatment in patients with metastatic NSCLC. The results showed similar efficacy between the two antibodies, with dostarlimab performing better in the PD-L1-positive subgroup. Additionally, the DCT treatment group had a longer progression-free survival, but there was no significant difference in overall survival between the two groups.
NATURE COMMUNICATIONS
(2023)
Review
Oncology
Jamie E. Chaft, Andreas Rimner, Walter Weder, Christopher G. Azzoli, Mark G. Kris, Tina Cascone
Summary: The treatment goal for early-stage lung cancer patients is cure, with surgical resection or radiotherapy as definitive local treatments along with adjuvant therapy to improve the likelihood of cure. New therapies lag behind due to inefficient trial designs and lengthy follow-ups, despite efforts to study surrogate endpoints to shorten trial durations.
NATURE REVIEWS CLINICAL ONCOLOGY
(2021)
Article
Oncology
Marc-Etienne Beaudet, Yves Lacasse, Catherine Labbe
Summary: This retrospective study examined whether patients with metastatic non-small cell lung cancer received palliative chemotherapy within 30 days before death. The study found that 22% of patients received chemotherapy during this time period, which was associated with decreased access to palliative care, higher rates of in hospital death, decreased use of medical aid, and a shorter overall survival.
Article
Oncology
Iktej Singh Jabbal, Saad Sabbagh, Mira Itani, Barbara Dominguez, Mohamed Mohanna, Valencia Henry, Hong Liang, Diana Saravia, Tiffany George, Zeina Nahleh, Evan Alley, Rafael Arteta-Bulos
Summary: Understanding the factors behind treatment refusal is crucial to improve cancer care and reduce disparities. This study analyzed data from the National Cancer Database and identified factors such as age, gender, income, insurance coverage, region, and comorbidity that were related to higher rates of chemotherapy refusal in patients with metastatic lung cancer. Retrospective studies exploring reasons for refusing standard treatment for NSCLC are lacking.
Article
Oncology
Wang Chun Kwok, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Summary: The independent risk factors for pemetrexed-induced nephrotoxicity in maintenance therapy were identified as non-evacuated third-space fluid, use of cisplatin during induction, and receiving more than 15 cycles of maintenance pemetrexed. To reduce the risk of nephrotoxicity, third-space fluid should be evacuated and carboplatin preferred over cisplatin whenever possible.
Review
Oncology
Stephanie P. L. Saw, Boon-Hean Ong, Kevin L. M. Chua, Angela Takano, Daniel S. W. Tan
Summary: Despite the advancements in treatment for advanced non-small-cell lung cancer (NSCLC), there is a renewed interest in neoadjuvant strategies for early-stage NSCLC. These strategies, including targeted therapy and immunotherapy, have the potential to greatly impact survival outcomes for early-stage NSCLC patients.
Article
Public, Environmental & Occupational Health
Xueyan Liang, Xiaoyu Chen, Huijuan Li, Xiaoxia Liu, Yan Li
Summary: This study evaluated the cost-effectiveness of the Chinese newly developed PD-L1 inhibitor sugemalimab plus chemotherapy (Sugema-Chemo) in China. The results showed that compared to chemotherapy alone, Sugema-Chemo increased QALY by 0.82 and life-years by 1.26, but with an average cost increase of $72,472. It was found that Sugema-Chemo might not be cost-effective for patients with metastatic NSCLC in China.
FRONTIERS IN PUBLIC HEALTH
(2023)
Article
Oncology
Wang Chun Kwok, Tan Fong Cheong, Ka Yan Chiang, James Chung Man Ho, David Chi Leung Lam, Mary Sau Man Ip, Terence Chi Chun Tam
Summary: The presence of non-evacuated third-space fluid in patients with advanced non-squamous NSCLC increases the risk of hematological toxicity when receiving Pemetrexed and platinum chemotherapy. Evacuation of third-space fluid in these patients can mitigate these adverse effects.
Article
Medicine, General & Internal
Mariano Provencio, Ernest Nadal, Jose L. Gonzalez-Larriba, Alex Martinez-Marti, Reyes Bernabe, Joaquim Bosch-Barrera, Joaquin Casal-Rubio, Virginia Calvo, Amelia Insa, Santiago Ponce, Noemi Reguart, Javier de Castro, Joaquin Mosquera, Manuel Cobo, Andres Aguilar, Guillermo Lopez Vivanco, Carlos Camps, Rafael Lopez-Castro, Teresa Moran, Isidoro Barneto, Delvys Rodriguez-Abreu, Roberto Serna-Blasco, Raquel Benitez, Carlos Aguado de la Rosa, Ramon Palmero, Florentino Hernando-Trancho, Javier Martin-Lopez, Alberto Cruz-Bermudez, Bartomeu Massuti, Atocha Romero
Summary: This study evaluated the efficacy of the neoadjuvant nivolumab plus chemotherapy regimen on operable stage III non-small-cell lung cancer (NSCLC) patients. The results showed that patients receiving the combination therapy had a higher rate of pathological complete response and longer survival, indicating the effectiveness of this treatment approach in this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Zhiwei Zheng, Huide Zhu, Ling Fang, Hongfu Cai
Summary: This study evaluated the cost-effectiveness of first-line additional sugemalimab in combination with chemotherapy vs. chemotherapy in the Chinese healthcare system using a three-state Markov model. The results showed that sugemalimab combination therapy is not economically advantageous for the first-line management of metastatic non-squamous NSCLC in China.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Health Care Sciences & Services
Teresa Hagan Thomas, Vicki A. Jackson, Heather Carlson, Simone Rinaldi, Angela Sousa, Andrea Hansen, Mihir Kamdar, Juliet Jacobsen, Elyse R. Park, William F. Pirl, Jennifer S. Temel, Joseph A. Greer
JOURNAL OF PALLIATIVE MEDICINE
(2019)
Article
Oncology
Joseph A. Greer, Jamie Jacobs, Nicole Pensak, James J. MacDonald, Charn-Xin Fuh, Giselle K. Perez, Alina Ward, Colleen Tallen, Alona Muzikansky, Lara Traeger, Frank J. Penedo, Areej El-Jawahri, Steven A. Safren, William F. Pirl, Jennifer S. Temel
Article
Oncology
Kelly E. Irwin, Elyse R. Park, Lauren E. Fields, Amy E. Corveleyn, Joseph A. Greer, Giselle K. Perez, Catherine A. Callaway, Jamie M. Jacobs, Andrew A. Nierenberg, Jennifer S. Temel, David P. Ryan, William F. Pirla
Review
Psychiatry
Hermioni L. Amonoo, Christina N. Massey, Melanie E. Freedman, Areej El-Jawahri, Halyna L. Vitagliano, William F. Pirl, Jeff C. Huffman
Review
Psychiatry
Miryam Yusufov, Ilana M. Braun, William F. Pirl
GENERAL HOSPITAL PSYCHIATRY
(2019)
Editorial Material
Oncology
Kelly E. Irwin, Beverly Moy, Lauren E. Fields, Catherine A. Callaway, Elyse R. Park, Lori Wirth
JOURNAL OF CLINICAL ONCOLOGY
(2019)
Article
Oncology
Daniel C. McFarland, Devika R. Jutagir, Barry Rosenfeld, William Pirl, Andrew H. Miller, William Breitbart, Christian Nelson
Article
Radiology, Nuclear Medicine & Medical Imaging
Efren J. Flores, Elyse R. Park, Kelly E. Irwin
JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
(2019)
Article
Health Policy & Services
Kelly E. Irwin, Eleanor B. Steffens, YooJin Yoon, Efren J. Flores, Helen P. Knight, William F. Pirl, Oliver Freudenreich, David C. Henderson, Elyse R. Park
PSYCHIATRIC SERVICES
(2019)
Article
Oncology
Jeremy S. Abramson, Kelly E. Irwin, Matthew J. Frigault, Jorg Dietrich, Brianne McGree, Justin T. Jordan, Andrew J. Yee, Yi-Bin Chen, Noopur S. Raje, Jeffrey A. Barnes, Benjamin Davis
Letter
Oncology
Maggie Watson, Wendy W. T. Lam, William Pirl, Richard Fielding
Article
Medicine, General & Internal
Elyse R. Park, Giselle K. Perez, Susan Regan, Alona Muzikansky, Douglas E. Levy, Jennifer S. Temel, Nancy A. Rigotti, William F. Pirl, Kelly E. Irwin, Ann H. Partridge, Mary E. Cooley, Emily R. Friedman, Julia Rabin, Colin Ponzani, Kelly A. Hyland, Susan Holland, Sarah Borderud, Kim Sprunck, Diana Kwon, Lisa Peterson, Jacob Miller-Sobel, Irina Gonzalez, C. Will Whitlock, Laura Malloy, Suhana de Leon-Sanchez, Maureen O'Brien, Jamie S. Ostroff
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2020)
Article
Oncology
Joseph A. Greer, Jamie M. Jacobs, Nicole Pensak, Lauren E. Nisotel, Joel N. Fishbein, James J. MacDonald, Molly E. Ream, Emily A. Walsh, Joanne Buzaglo, Alona Muzikansky, Inga T. Lennes, Steven A. Safren, William F. Pirl, Jennifer S. Temel
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2020)
Article
Health Policy & Services
Hanneke Poort, Jamie M. Jacobs, William F. Pirl, Jennifer S. Temel, Joseph A. Greer
PALLIATIVE & SUPPORTIVE CARE
(2020)